Widely read:
The pharma major doubled profits last year — can it repeat the dose in FY26?
Q1 marks a crucial test of Lupin’s recovery story. With high expectations riding on new launches, margin gains, and US market momentum, the stakes are high. But can the turnaround sustain — or is the rally already priced in?
Lupin is set to announce its Q1 FY26 results on August 5, 2025, and expectations are running high. After staging a solid turnaround in FY25, investors are now focused on whether India’s leading pharmaceutical company can sustain its recovery on a higher base — and defend its profit margins amid evolving global dynamics.
The April–June quarter marks a critical checkpoint: Is Lupin’s operational revival for real, or was FY25 an exceptional year unlikely to be repeated?
Recent Performance Recap: A Turnaround in Motion
Lupin ended FY25 on a strong note. In Q4 FY25, standalone net profit more than doubled YoY to Rs 782 crore, while revenue rose 14 per cent to Rs 5,667 crore. This performance was powered by:
- North America sales up 19 per cent YoY (Rs 2,261 crore)
- India formulation sales up 7 per cent YoY (Rs 1,711 crore)
- EBITDA margins touching multi-year highs (~13 per cent)
The company’s FY25 full-year profit jumped ~71 per cent, reflecting improved operating efficiency, cost control, and a more focused portfolio strategy.
Importantly, Lupin’s comeback began exactly a year ago in Q1 FY25, when net profit surged 77 per cent YoY to Rs 801 crore, and revenue grew 16.2 per cent to Rs 5,514 crore. That quarter laid the foundation for four straight quarters of double-digit revenue growth and expanding profitability.
Q1 FY26 Expectations: Growth on a Higher Base
Revenue Growth: Steady, Not Spectacular
Analysts expect high single-digit to low double-digit revenue growth YoY in Q1 FY26. With last year’s base now elevated, absolute growth may moderate — but should still signal healthy business momentum.
- US generics, which made up ~37 per cent of FY25 revenue, are likely to remain the key growth engine, driven by:
- New launches in complex and limited-competition segments (e.g., inhalers, ophthalmics)
- Stabilising the pricing environment in the US market
- India, Lupin’s second-largest segment, is expected to exhibit stable growth in chronic therapy areas, including respiratory, diabetes, and cardiology, driven by brand leadership and new product launches.
Profitability and Margins: The Real Test
Margins will be closely tracked. In Q1 FY25, Lupin delivered an EBITDA margin of ~24 per cent — a standout figure in the industry. Investors will be watching whether:
- Operating efficiencies continue to drive cost savings
- Product mix remains favourable, with higher contributions from complex generics
- R&D spending stays in check without sacrificing the pipeline
A net profit near or above Rs 800 crore would suggest that Lupin’s turnaround is holding up well. Any sequential improvement over Q4’s Rs 782 crore will reinforce investor confidence.
Peers’ Performance: Mixed Signals from the Sector
Lupin’s Q1 results will be evaluated in the context of recent earnings from other top pharma players:
- Sun Pharma posted a 9 per cent YoY revenue rise in Q1 FY26 but saw net profit fall ~20 per cent, citing a high base and US pricing pressures.
- Dr. Reddy’s reported strong 11 per cent revenue growth but just a 2 per cent increase in profit, indicating cost pressures.
- Cipla experienced muted revenue growth (+3.9 per cent) but a 10 per cent increase in profit, driven by margin gains.
Compared to these peers, Lupin’s trajectory — if maintained — would stand out for its consistent margin expansion and higher profit growth.
Strategic Updates: A Sharper Focus on Complex Therapies
New Approvals in High-Value Segments
Lupin recently received US FDA approvals for key diabetes products, including the generic Liraglutide (Victoza) and Glucagon injection. These represent its entry into the GLP-1 agonist market, a rapidly growing segment. While these won’t reflect in Q1 numbers, they strengthen medium-term growth visibility.
Pipeline Execution and Launch Cadence
- In Q1 FY25, Lupin launched multiple complex generics in the US, including its first inhalation product.
- The company also received 6 ANDA approvals during that quarter — suggesting an ongoing rhythm of launches and filings.
- Continued traction in high-margin segments, such as respiratory and ophthalmology, could boost future margins.
Operational Discipline
- Lupin’s plants have seen improvements in compliance, aiding in shorter approval timelines.
- The company ended FY25 with near-zero net debt, reflecting capital discipline.
- Further cost optimisation is expected to help maintain financial resilience in FY26.
Stock Rating and Investment Outlook
Lupin currently holds a 3-star Value Research Stock Rating, indicating a neutral investment case — with both upside potential and valuation risks.
| Score | Rating | Comment |
| Quality | 5/10 | Improving profitability, but past volatility still weighs on the score |
| Growth | 7/10 | Strong YoY profit and revenue growth, supported by new launches |
| Valuation | 4/10 | Stock trades at ~32× earnings; premium pricing limits margin of safety |
| Momentum | 3/10 | ~27 per cent return in 1 year; outperforming sector and Nifty Pharma Index |
The valuation score remains a concern. With the stock already doubling over the past year, much of the turnaround appears to be priced in. This puts pressure on Lupin to deliver consistent execution going forward.
Bottom Line: Can Lupin Maintain Its Growth Prescription?
Lupin’s Q1 FY26 earnings will be more than a quarterly snapshot — they will act as a barometer of the company’s resilience. With recent history on its side, a clean balance sheet, and momentum in the US and Indian markets, the company seems poised for another solid quarter.
But the bar is high. Even minor setbacks in profit or margin expansion could invite caution, given Lupin’s premium valuation. On the other hand, if the company achieves stable growth, margin gains, and pipeline progress, it could justify a re-rating of its quality score — and potentially unlock further upside in the stock.
As the earnings season unfolds, all eyes will be on whether Lupin can continue writing its comeback story — one profitable quarter at a time.
Want to Know if Lupin Is a Good Investment Now?
Get full access to our stock ratings, analyst views, and future outlook for Lupin and other companies.
Join Value Research Stock Advisor and unlock smarter investing.
Disclaimer: This is not a stock recommendation. This story was created with the assistance of artificial intelligence and has been reviewed by human experts for accuracy and is intended for informational purposes only. Please take it with a grain of salt and conduct your own research or consult a financial advisor before making any investment decisions.
Disclaimer: This content is for information only and should not be considered investment advice or a recommendation.
For grievances: [email protected]
Ask Value Research 
New episodes every Friday 
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
